Vigil Neuroscience logo

Vigil Neuroscience

Cambridge, MA

Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.

vigilneuro.com

Company Details

Founded

2020

Employees

67 employees

Raised

$180,000,000

Headquarters Location

Cambridge, MA

Public

Yes

Acquired

Yes

CEO

Ivana Magovčević-LiebischIvana Magovčević-Liebisch

Company Collections

These are collections Vigil Neuroscience is a part of. Click on the collection name to view similar companies.

Vigil Neuroscience Headquarters Location

300 Technology Square 8th Floor, Cambridge, MA 02139

Total Amount Raised: $180,000,000

Vigil Neuroscience Funding Rounds

  • Post Ipo Equity

    $40,000,000

    Post Ipo Equity Investors

    Sanofi
  • IPO

    Unknown

  • Series B

    $90,000,000

    Series B Investors

    Vida Ventures
    OrbiMed Advisors
    Lightstone Ventures
    Hatteras Venture Partners
    Surveyor Capital
    Cormorant Asset Management
    Deep Track Capital
    Rock Springs Capital
    Northpond Ventures
    Pivotal bioVenture Partners
    Invus
    Atlas Venture
    Logos Capital
  • Series A

    $50,000,000

    Series A Investors

    Atlas Venture
    Northpond Ventures
    Hatteras Venture Partners
    Alexandria Venture Investments
Funding info provided by Diffbot.

Vigil Neuroscience Reviews

0 out of 5 stars

Based on 0 reviews

Review data

Share your thoughts

Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Vigil Neuroscience.

Recent reviews